• 1
    Olivieri I, D'Angelo S, Palazzi C, Padula A, Mader R, Khan MA. Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis. Curr Rheumatol Rep 2009; 11: 3218.
  • 2
    Yagan R, Khan MA. Confusion of roentgenographic differential diagnosis in ankylosing hyperostosis (Forestier's disease) and ankylosing spondylitis. In: Khan MA. Ankylosing spondylitis and related spondyloarthropathies. Spine: state of the art reviews. Vol. 4. Philadelphia: Haley & Belfus; 1990. p. 56175.
  • 3
    Dar G, Peleg S, Masharawi Y, Steinberg N, Rothschild BM, Hershkovitz I. The association of sacroiliac joint bridging with other enthesopathies in the human body. Spine 2007; 32: E3038.
  • 4
    Kim TJ, Kim TH, Jun JB, Joo KB, Uhm WS. Prevalence of ossification of posterior longitudinal ligament in patients with ankylosing spondylitis. J Rheumatol 2007; 34: 24602.
  • 5
    Ono K, Yonenobu K, Miyamoto S, Okada K. Pathology of ossification of the posterior longitudinal ligament and ligamentum flavum. Clin Orthop Relat Res 1999; ( 359): 1826.
  • 6
    Resnick D, Niwayama G. Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology 1976; 119: 55968.
  • 7
    Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004; 63: 104655.
  • 8
    Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 2009; 61: 76471.
  • 9
    Kasai Y, Kawakita E, Sakakibara T, Akeda K, Uchida A. Direction of the formation of anterior lumbar vertebral osteophytes. BMC Musculoskelet Disord 2009; 10: 4.
  • 10
    Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes [review]. Arthritis Rheum 2008; 58: 64956.
  • 11
    Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008; 10: R104.
  • 12
    Forestier J, Rotes-Querol J. Senile ankylosing hyperostosis of the spine. Ann Rheum Dis 1950; 9: 32130.
  • 13
    Koga H, Sakou T, Taketomi E, Hayashi K, Numasawa T, Harata S, et al. Genetic mapping of ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet 1998; 62: 14607.
  • 14
    Kiss C, Szilagyi M, Paksy A, Poor G. Risk factors for diffuse idiopathic skeletal hyperostosis: a case-control study. Rheumatology (Oxford) 2002; 41: 2730.
  • 15
    Mader R, Novofestovski I, Adawi M, Lavi I. Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum 2009; 38: 3615.
  • 16
    Vezyroglou G, Mitropoulos A, Antoniadis C. A metabolic syndrome in diffuse idiopathic skeletal hyperostosis: a controlled study. J Rheumatol 1996; 23: 6726.
  • 17
    Mader R, Sarzi-Puttini P, Atzeni F, Olivieri I, Pappone N, Verlaan JJ, et al. Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. Rheumatology (Oxford) 2009; 48: 147881.
  • 18
    Mata S, Fortin PR, Fitzcharles MA, Starr MR, Joseph L, Watts CS, et al. A controlled study of diffuse idiopathic skeletal hyperostosis: clinical features and functional status. Medicine (Baltimore) 1997; 76: 10417.
  • 19
    Olivieri I, D'Angelo S, Cutro MS, Padula A, Peruz G, Montaruli M, et al. Diffuse idiopathic skeletal hyperostosis may give the typical postural abnormalities of advanced ankylosing spondylitis. Rheumatology (Oxford) 2007; 46: 170911.
  • 20
    Resnick D, Shaul SR, Robins JM. Diffuse idiopathic skeletal hyperostosis (DISH): Forestier's disease with extraspinal manifestations. Radiology 1975; 115: 51324.
  • 21
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 22
    Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000; 12: 23947.
  • 23
    Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 44252.
  • 24
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 118793.
  • 25
    Davis J Jr, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis [letter]. Arthritis Rheum 2004; 51: 3024.
  • 26
    Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 340212.
  • 27
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 213646.
  • 28
    Van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 306370.
  • 29
    Van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 132431.
  • 30
    Van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11: R127.
  • 31
    Baraliakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis—evidence for major individual variations in a large proportion of patients. J Rheumatol 2009; 36: 9971002.
  • 32
    Resnick D, Niwayama G. Diffuse idiopathic skeletal hyperostosis (DISH). In: Diagnosis of bone and joint disorders. Vol. 3. Philadelphia: WB Saunders; 1975. p. 146395.
  • 33
    Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007; 66: 9105.
  • 34
    Dihlmann W. Current radiodiagnostic concept of ankylosing spondylitis. Skeletal Radiol 1979; 4: 17988.
  • 35
    Wanders A, Landewe R, Spoorenberg A, de Vlam K, Mielants H, Dougados M, et al. Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis 2004; 63: 16014.
  • 36
    Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximab. Rheumatology (Oxford) 2007; 46: 14503.
  • 37
    Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab. Ann Rheum Dis 2005; 64: 14626.
  • 38
    Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009; 60: 93102.
  • 39
    Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging–evident sacroiliitis and HLA–B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008; 58: 34138.
  • 40
    Van der Heijde DM. Radiographic imaging: the ‘gold standard’ for assessment of disease progression in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 Suppl 1: 916.
  • 41
    Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005; 64: 7304.